Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GSK Wades Into The Pooled Approach To Tropical Disease Research

Executive Summary

GlaxoSmithKline CEO Andrew Witty's proposal for companies to pool their patents to develop medicines for neglected tropical diseases is a somewhat unusual call for collaboration in the pharmaceutical industry, but not entirely without precedent

You may also be interested in...



Effectiveness Of Priority Review Voucher, Orphan Status Part Of Tropical Disease Hearing

September public hearing will continue FDA's look into rare and neglected disease drug development.

Pre-Competitive Collaboration Would Help Pharmaceutical Productivity Crisis - If Lawyers Could Get Out Of The Way

CAMBRIDGE, Mass. - Greater R&D collaboration was the theme of the day at the star-studded U.S.-India Chamber of Commerce biopharma and healthcare summit

Pre-Competitive Collaboration Would Help Pharmaceutical Productivity Crisis - If Lawyers Could Get Out Of The Way

Pre-commercial collaborations and R&D network expansions fall in the cross hairs of IP lawyers, who look to protect everything they can as intellectual property. But with big pharma desperate to speed up drug development and conserve resources, it's likely the R&D heads have the upper hand, at least for now.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS050724

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel